QPS Holdings LLC
11
1
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
27.3%
3 terminated/withdrawn out of 11 trials
62.5%
-24.0% vs industry average
27%
3 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)
Role: collaborator
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Role: collaborator
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer
Role: collaborator
Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer
Role: collaborator
IPD in RRMM Characterized with Genomic Abnormalities of Adverse Prognostic
Role: collaborator
Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy.
Role: collaborator
Assessment of the Pharmacodynamic and Pharmacokinetic Interaction of Remimazolam and Remifentanil
Role: collaborator
A Study to Compare Pharmacokinetics of GB1211
Role: collaborator
Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults
Role: collaborator
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
Role: collaborator
First Time in Human Study of Protexia
Role: collaborator
All 11 trials loaded